Want to hire this expert for a project? Request a quote for free.
USD 60 /hr
Hire Dr. Paromita R.
USD 60 /hr
Scientist, Scientific Reviewer and Editor with 6+ years of experience in drug discovery.
Subject Matter Expertise
Writing Clinical Trial Documentation, Technical Writing
Freelance Scientific Editor
July 2019 - Present
Lecker Labs Canada Inc
July 2018 - Present
Freelance Expert Scientific Reviewer
Edanz Group Ltd
June 2016 - Present
September 2016 - July 2018
University of California, San Francisco
August 2010 - August 2014
University of Calcutta
August 2003 - April 2010
- Certification details not provided.
(2016). A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma . Annals of Oncology.
(2016). Conformational selection underpins recognition of multiple DNA sequences by proteins and consequent functional actions . Physical Chemistry Chemical Physics.
(2015). Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression . Breast Cancer Research.
(2013). Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling . Molecular Cancer Therapeutics.
(2013). Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt . PLoS ONE.
(2011). High-Affinity Quasi-Specific Sites in the Genome: How the DNA-Binding Proteins Cope with Them . Biophysical Journal.
(2011). Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance . Epigenomics.
(2011). A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer . British Journal of Cancer.
(2016). Outcome of Combining Epigenetic Drugs with Other Treatments in the Clinic . Medical Epigenetics.